Drug Discovery World

JANUARY 15, 2024

For an additional $28 million, Lantheus has obtained an option to exclusively license Perspective’s neuroendocrine tumours treatment Pb212-VMT-⍺-NET, or to co-develop certain early stage therapeutic candidates targeting prostate cancer. of Perspective’s shares for up to $33 million.

Targeted Protein Degradation 147

Targeted Protein Degradation Drugs Small Molecule Licensing 147

The Pharma Data

JULY 22, 2021

The companies will equally share worldwide development costs, commercialization expenses, and profits. This collaboration has the potential to be transformational, as it combines our leadership in targeted protein degradation with Pfizer’s global capabilities and deep expertise in breast cancer.

Targeted Protein Degradation 52

Targeted Protein Degradation Therapies Clinical Trials Treatment 52

Drug Discovery World

OCTOBER 16, 2023

Dr Tralau-Stewart says: “Indeed, many academic institutions have established new ways of supporting the discovery pipeline, providing tech transfer offices to support licensing, and entrepreneurship and start-up support through fundraising, accelerators, and incubators.

Drugs 189

Drugs Science Therapies Targeted Protein Degradation 189